CDK9 and acute myeloid leukemia: As part of a medicinal chemistry and drug discovery program, we identified CDDD11-8 as a potent, orally bioavailable CDK9 inhibitor selective for CDK9 (with >50-fold selectivity over other CDKs assessed) that reduced in vitro and in vivo growth of human cell line models of acute myeloid leukaemia [30].